Publication: Topoisomerase 1A, HER,2neu and Ki67 expression in paired primary
and relapse ovarian cancer tissue samples
Authors
Surowiak, P. ; Materna, V. ; Kaplenko, I. ; Spaczynski, M. ; Dietel, Manfred ; Lage, H. ; Zabel, M.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
In the present study we examined prognostic
value of immunohistochemical estimation of
topoisomerase 1A (TOP 1A) and HER-2/neu expression
in ovarian cancers treated with platinum-based drugs but
not with topotecan and the relation between expression
of these proteins on the one hand and intensity of
proliferation (Ki67) on the other. The analyses were
performed on 73 samples of ovarian carcinoma
originating from 43 first-look laparotomies (FLL) and, in
30 cases, from secondary cytoreductions (SCR)(after
chemotherapy) from the same patients. In paraffin
sections immunohistochemical reactions were performed
using antibodies directed to HER-2/neu, TOP 1A and
Ki67. Kaplan-Meier’s analysis disclosed a shorter
overall survival time in cases with augmented expression
of TOP 1A at FLL and with higher expression of Ki67 at
SCR. A shorter progression-free time was detected in
cases with higher proportion of Ki67 positive cells at
FLL. No relationship could be disclosed between HER-
2/neu expression and the studied clinicopathological
parameters. The studies confirmed high value of Ki67
estimation. The augmented expression of TOP 1A was
demonstrated to represent an unfavourable prognostic
factor. Thus, in cases with elevated expression of TOP 1A application of topotecan-based therapeutic schemes
should be considered.
publication.page.subject
Citation
item.page.embargo
Ir a EstadÃsticas
Sin licencia Creative Commons.